Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (
about
Approved Antiviral Drugs over the Past 50 YearsMoving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trialRaltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infectionHIV-1 drug resistance and resistance testing.Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.Evolution of HIV treatment guidelines in high- and low-income countries: converging recommendationsDurability of antiretroviral therapy and predictors of virologic failure among perinatally HIV-infected children in Tanzania: a four-year follow-up.Efficacy of second-line antiretroviral therapy among people living with HIV/AIDS in Asia: results from the TREAT Asia HIV observational databaseGuidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand.Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in AfricaEfficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN TrialA prospective cohort study of neurocognitive function in aviremic HIV-infected patients treated with 1 or 3 antiretrovirals.HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial.Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.Clinical and Virologic Outcomes After Changes in First Antiretroviral Regimen at 7 Sites in the Caribbean, Central and South America NetworkBrief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study.Doubly blind: a systematic review of gender in randomised controlled trials.Assessment of non-standard HIV antiretroviral therapy regimens at Lighthouse Trust in Lilongwe, MalawiRaltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority studyBone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy.Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern.First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.Raltegravir as antiretroviral therapy in HIV/AIDS.Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature.Integrase strand transfer inhibitors in the management of HIV-positive individuals.Integrase Strand Transfer Inhibitors in HIV Therapy.Ageing with HIV: a multidisciplinary review.Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients.Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection.Dutrebis (lamivudine and raltegravir) for use in combination with other antiretroviral products for the treatment of HIV-1 infection.Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere?Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa.Association of the HLA-B*53:01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir.HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa.HIV viral kinetics and T cell dynamics in antiretroviral naïve persons starting an integrase strand transfer inhibitor and protease inhibitor regimen.Efficacy of raltegravir-containing regimens in antiretroviral-naïve and -experienced individuals in routine clinical practice.Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: a randomized trial.Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in Europe.
P2860
Q27755387-A39B567F-A0CF-49C4-9DF3-F3F64B84F12AQ28540037-534ECFBB-4FF0-4513-8F7B-A47E0CDE0371Q28543732-50861492-0C5E-414C-8784-626FD8A5B8A7Q30245693-D51514EB-377F-4902-9C10-39C4B841A40DQ33712438-3E1A39C9-704B-446B-AC4A-17CCBEDF5F7EQ34321843-07A6F5CF-BEA6-4445-A3F6-4C4E77CD8472Q34475728-571994FF-3EDB-4310-9888-2D0748A398CCQ34977431-F126BADE-FAEA-4D13-A968-75BD26E7183AQ35530299-E1623622-87FD-491F-9816-22B7BA2F68EEQ35588154-B2251C9D-3371-4C0F-9194-2A08BD9B11BCQ35853812-BECBAB05-FAB0-4869-8687-1496B5C66845Q36013412-D39E6E54-C380-4C53-AED9-A7DF015F8F08Q36293999-49210E91-A226-4D5D-B8A0-3A156810CD87Q36377132-4D42C9F7-E3C8-44A5-A52A-4B722268E153Q36426953-D1956842-3E67-4B66-A9FF-7812AC674F88Q36462119-2A3EEF95-8677-4174-8696-2B1468C5902BQ36721002-FC83D01D-7CEF-4D85-B68F-48B5EABFB4AAQ36805845-6173615C-C8B9-4CD8-AC63-2A02BE9E8881Q36893580-A47BC5E6-5090-4755-B97E-47F3CCBD5876Q37021431-55FDDD20-B6BD-4AAB-8251-AB0EE44325B9Q37272765-33C3A9E0-682F-46C3-AD0C-12D67C853173Q37461250-4F6A06D8-F23B-4700-AB56-4C0D14459A5CQ37732266-A837FC33-E860-4B25-8C20-1F037ADE5064Q38168587-D30B6D33-AAB9-4CA9-8784-09D892D78231Q38170576-601C1D94-51E1-40A4-BA35-3FB7082F8D9CQ38192022-1592B8C8-C6FE-43E8-83FD-F2F3CE0BF13AQ38240974-2F1049DA-DF5F-4144-8816-FF660246BBD4Q38490362-557A3261-1B3D-46BC-8E37-7FD657143255Q38527537-99919A1B-83AB-44F5-B483-B922FA4E1A3DQ38570500-A57F0791-0B66-4ADF-8475-C44999C93662Q38620257-B9DBAC7A-6E77-4947-B4FC-02AFFDE21430Q38737182-4626847B-4174-41E2-8CFA-DF1BE3372407Q38853866-C04BF426-C846-4280-9756-FC247E127CDBQ38860427-66866325-93A8-4057-A0BE-B544D3F691D2Q39360243-F1B128DC-BA0E-408B-B7DF-65198F5CD81FQ40353844-3B6642E1-F080-4D13-A7A1-EC7CF0BA8283Q40474552-4A667685-FA61-4163-BD02-4A6506D08967Q40820470-159432EC-F8A2-4181-9A20-90F543084931Q40846333-28615030-875E-4021-ADC9-22E4BD055210Q41293200-3DCF6E37-6953-421A-A6C2-F3569944964F
P2860
Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Ritonavir-boosted lopinavir pl ...... ndard first-line ART regimen (
@en
Ritonavir-boosted lopinavir pl ...... tandard first-line ART regimen
@nl
type
label
Ritonavir-boosted lopinavir pl ...... ndard first-line ART regimen (
@en
Ritonavir-boosted lopinavir pl ...... tandard first-line ART regimen
@nl
prefLabel
Ritonavir-boosted lopinavir pl ...... ndard first-line ART regimen (
@en
Ritonavir-boosted lopinavir pl ...... tandard first-line ART regimen
@nl
P2093
P1433
P1476
Ritonavir-boosted lopinavir pl ...... ndard first-line ART regimen (
@en
P2093
D A Cooper
J-M Molina
P304
P356
10.1016/S0140-6736(13)61164-2
P407
P577
2013-06-01T00:00:00Z